This filing is a routine disclosure of existing insider ownership. No trading signal or catalyst is implied. Monitor for upcoming Phase 2 AKI trial results, which could trigger warrant expiration and provide a binary catalyst.
Price Chart
Executive Summary
Alafi Capital Co LLC filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing ownership of 5,112,345 common shares and warrants to purchase 130,651 shares at $7.15 in CalciMedica. This is a routine administrative filing that does not convey new material information about the company's operations or financials.
Key Facts
- Alafi Capital Co LLC reported beneficial ownership of 5,112,345 shares of common stock.
- Alafi also holds warrants to purchase 130,651 shares of common stock at an exercise price of $7.15 per share.
- Warrants were issued July 22, 2025, and expire on the earlier of December 31, 2026, or 30 days after public disclosure of topline results from a Phase 2 acute kidney injury trial.
- Form 3 is an initial ownership filing, not a trade or material corporate event.
Financial Impact
No financial impact; the filing merely discloses existing ownership positions.
Risk Factors
- Warrants expire upon disclosure of Phase 2 AKI results, which could create overhang if exercised.
- No new operational or financial data is provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (CALC) — Batch item 1 | 0000912282-26-000963 |
| Document: 0000912282-26-000963-index.html | 0000912282-26-000963 |
| Document: 0000912282-26-000963.txt | 0000912282-26-000963 |
| 3 Filing (CALC) — Batch item 4 | 0000912282-26-000963 |
| Document: 0000912282-26-000963-index.html | 0000912282-26-000963 |
| Document: 0000912282-26-000963.txt | 0000912282-26-000963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.02 | awaiting T+20 | — | $1.30 (−27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 30, 2026 26d ago | 424B5 | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 2, 2026 7w ago | 8-K | $2.10 $1.65 | ▲ +21.43% | ▲ +21.28% | $1.30 (+38.10%) |
Aug 11, 2026 10w ago | 8-K | $0.6577 $0.4590 | ▲ +30.21% | ▲ +29.15% | $1.30 (−97.66%) |
Aug 11, 2026 10w ago | Press Release | $0.6577 $0.4590 | ▼ −30.21% | ▼ −29.15% | $1.30 (+97.66%) |
Jul 10, 2026 15w ago | 3 | $0.8178 $0.6590 | ▼ −19.42% | ▼ −22.60% | $1.30 (+58.96%) |
Jun 24, 2026 17w ago | 8-K | $0.5973 $0.7159 | ▼ −19.86% | ▼ −19.18% | $1.30 (−117.65%) |
May 12, 2026 23w ago | 8-K | $0.6300 $0.9320 | ▲ +47.94% | ▲ +49.66% | $1.30 (+106.35%) |
Mar 12, 2026 32w ago | EFFECT | $0.7260 $0.6180 | ▼ −14.88% | ▼ −16.85% | $1.30 (+79.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers